U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07067463) titled 'A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis' on July 03.
Brief Summary: Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for a minimum of 120 weeks. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Multiple Sclerosis (MS) Primary Progressive
Intervention:
DRUG: Orelab...